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Department of Comparative 
Pathobiology, College of Veterinary 
Medicine, Purdue University, West 
Lafayette, IN, USA
Abstract: The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory 
peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. RR 
(2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of proinflamma-
tory cytokines, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, in methicillin-resistant 
Staphylococcus aureus USA 300-0114 skin lesions. Furthermore, the combined therapy of 
RRIKA (1%) and lysostaphin (0.5%) had significantly higher antistaphylococcal and anti-
inflammatory activity compared to monotherapy. This study supports the potential use of these 
peptides for topical treatment of methicillin-resistant Staphylococcus aureus skin infections.
Keywords: antimicrobial peptides, MRSA, lysostaphin, skin infection, mice
Introduction
Bacterial infections, especially those caused by Staphylococcus aureus, are the most 
significant complication encountered in the management of wounds.1 Furthermore, 
multidrug-resistant S. aureus strains and their secreted toxins are responsible for 
interfering with the wound-healing process and creating portals of entry for systemic 
complications in affected patients.2 With the increasing incidence of staphylococcal 
resistance to topical antimicrobials, such as mupirocin and fusidic acid,3–5 there is a 
pressing need to develop novel antimicrobials and new approaches to circumvent this 
burgeoning problem. Recently, there has been increased interest in the development 
of antimicrobial peptides (AMPs) as novel therapeutics, due to their high potency, 
broad spectrum of activity, and reduced potential for resistance development.6,7 In 
addition to the potent bactericidal activity of AMPs, the recognized anti-inflammatory 
response of certain AMPs should be an advantage in the treatment of S. aureus skin 
infections.8
In a recent study, we described two novel short peptides – RR (WLRRIKAWLRR) 
and RRIKA (WLRRIKAWLRRIKA) – with potent bactericidal activity in vitro against 
multiple clinical isolates of methicillin-resistant S. aureus (MRSA).6 In particular, the 
peptides were active against the highly virulent MRSA USA 300-0114, a community- 
associated strain responsible for outbreaks of staphylococcal skin and soft-tissue 
infections in the US.9 Moreover, RR and RRIKA were superior in reducing adherent 
biofilms of both S. aureus and Staphylococcus epidermidis when compared to conven-
tional antibiotics. Furthermore, both RR and RRIKA enhanced the antistaphylococcal 
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activity of lysostaphin in vitro more than 1,000-fold.6 Although 
lysostaphin demonstrated potent efficacy against MRSA infec-
tions in different animal models,10–12 its therapeutic potential 
was hampered by the emergence of bacterial resistance.10,13 
In light of our previous results, showing enhancement of the 
antimicrobial effectiveness of lysostaphin against MRSA when 
combined with AMPs in vitro,6 we moved forward with an in 
vivo experiment in a mouse model of MRSA skin infection.
Materials and methods
Bacterial isolate
We obtained the community-acquired MSRA strain NRS384 
(MRSA USA 300-0114) isolated from a wound from a patient 
in Mississippi, USA. The strain is resistant to erythromycin 
and tetracycline; positive for mec (subtype IV); pvl+/−; mul-
tilocus sequence type 8−; eGenomic spa type 1, eGenomic spa 
repeats YHGFMBQBLO; Ridom spa type t008; agr grp I.
Peptides and antibacterial agents
RR and RRIKA were synthesized by GenScript (Piscataway, 
NJ, USA). Recombinant lysostaphin was purchased from 
Ambi Products (Lawrence, NY, USA). Linezolid and fusidic 
acid were purchased from Chem-Impex International (Wood 
Dale, IL, USA).
Mouse infection
Female BALB/c mice (6–8 weeks old) were obtained from 
Harlan Laboratories (Indianapolis, IN, USA). All procedures 
were approved by the Purdue University Animal Care and 
Use Committee (1207000676). The murine model of MRSA 
skin infection has been described before.14,15 Eight groups of 
mice (n=5) were inoculated with 40 µL of MRSA USA 300 
(3×107 CFU) intradermally. Forty-eight hours after infection 
and formation of an open wound, six 6 groups were treated 
topically with either 2% fusidic acid, 2% RR, 2% RRIKA, 
1% RRIKA, 0.5% lysostaphin, or 1% RRIKA plus 0.5% 
lysostaphin formulated in 20 mg petroleum jelly. One group 
received vehicle only (petroleum jelly), and the last group 
was treated orally with linezolid (25 mg/kg). All groups were 
treated twice a day for 3 days. Twenty-four hours after the 
last treatment, mice were humanely killed, the area around 
the wound lightly swabbed with 70% ethanol, and the wound 
(around 1 cm2) excised for bacterial counting after homog-
enization in 1 mL tryptic soy broth.
Cytokine detection
Enzyme-linked immunosorbent assay (ELISA) develop-
ment kits for detection of cytokines were purchased from 
R&D Systems (Minneapolis, MN, USA). Homogenized 
skin lesions after bacterial counting were centrifuged at 
15,000 rpm for 10 minutes. The supernatants were removed 
and kept at −20°C until analyzed. The supernatants were 
examined for cytokine production: tumor-necrosis fac-
tor (TNF)-α, interleukin (IL)-6, and IL-1β using ELISA 
as described before.16 Cytokine levels were expressed as 
percentage change relative to negative control.
Statistical analyses
Data are presented as means ± standard deviation. Statisti-
cal analyses were performed using GraphPad Prism 6.0 
(GraphPad Software, La Jolla, CA, USA). P-values were 
calculated by the two-tailed Student’s t-test. P-values ,0.05 
were considered significant.
Results and discussion
As shown in Figure 1, all treatments significantly reduced 
the mean bacterial counts compared with the control group 
(P0.01). Among groups treated with monotherapy, the 
group treated with 2% RRIKA had the highest reduction 
in CFU (2.08±0.20 log
10
), followed by 2% fusidic acid 
(1.94±0.36 log
10
), 2% RR (1.83±0.30 log
10
), and linezolid 
(1.74±0.53 log
10
). Groups treated with 0.5% lysostaphin or 
1% RRIKA achieved a significant reduction of 1.79±0.56 
log
10
 and 1.08±0.36 log
10
, respectively, when compared with 
Figure 1 Efficacy of treatment of methicillin-resistant Staphylococcus aureus skin 
lesions with RRIKA (2%), RR (2%), fusidic acid (2%), linezolid (25 mg/kg), RRIKA 
(1%), lysostaphin (0.5%), combined therapy of RRIKA (1%) and lysostaphin (0.5%), 
and petroleum jelly (negative control) twice daily for 3 days. The two-tailed Student’s 




















































































Efficacy of peptides in a mouse model of MRSA skin infection
the control group (P0.01) (Figure 1). The combination 
therapy (0.5% lysostaphin with 1% RRIKA) was significantly 
more effective than treatment with RRIKA or lysostaphin 
alone, and achieved statistically significant bacterial reduc-
tion of 2.65±0.44 log
10
 compared to the negative control 
(P0.01). The bacterial reduction in the combined therapy 
was also statistically significant compared to monotherapy 
(P,0.05) or control antibiotics (P,0.05). Previously, RR 
and RRIKA showed potent immunomodulatory activities in 
vitro through inhibition of mitogen-activated protein kinase 
(MK2).17,18 In this study, topical treatment with RRIKA 
and RR significantly reduced TNFα and IL-6 production 
in MRSA skin lesions. As shown in Figure 2A and B, 2% 
RR and 2% RRIKA reduced the TNFα level by 49% and 
Figure 2 The effect of peptides on cytokines TNFα (A), IL-6 (B), and IL-1β (C) production in methicillin-resistant Staphylococcus aureus skin lesions. Tissue homogenate 
supernatants were examined for cytokine production using the enzyme-linked immunosorbent assay. Cytokine levels were expressed as percentage change relative to 
negative control. Data are presented as means ± standard deviation from duplicates consisting of four mice per group. Statistical analysis was calculated by the two-tailed 
Student’s t-test. P-values ,0.05 were considered significant (*).








































































































































































































































































































































56%, respectively, while the IL-6 level was reduced by 29% 
and 60%, respectively. Treatment with 0.5% lysostaphin 
and 2% fusidic acid caused 39% and 29% reduction of the 
TNFα level, respectively, and 13% and 25% reduction of the 
IL-6 level, respectively, which is in agreement with previ-
ous findings.19,20 There was a synergistic anti-inflammatory 
response observed when 0.5% lysostaphin was combined 
with 1% RRIKA. The combined therapy significantly 
reduced TNFα and IL-6 levels by 62% and 67%, respectively. 
On the other hand, none of the treatments interfered with 
IL-1β production, which is necessary for S. aureus clearance 
in cutaneous infections (Figure 2C).21–22
In this study, topical application of RR and RRIKA was 
shown to be very effective in reducing the bacterial load 
in MRSA skin lesions. Moreover, peptides reduced the 
release of TNFα and IL-6, which might benefit the heal-
ing of infected wounds.23–27 In addition, the combination 
of RRIKA with lysostaphin was significantly more effec-
tive in the treatment of MRSA skin lesions than treatment 
with either peptide alone. This combination therapy is 
also expected to overcome some of the limitations associ-
ated with lysostaphin monotherapy through hindering the 
emergence of bacterial resistance and lowering the required 
therapeutic dose.
In conclusion, our findings in MRSA skin lesions should 
significantly impact and inform efforts to use a combination 
of anti-inflammatory and AMP therapies as novel topical 
treatment options for multidrug-resistant pathogens.
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